RUNX1/CEBPA Mutation in Acute Myeloid Leukemia Promotes Hypermethylation and Indicates for Demethylation Therapy.

Area of Science:

• Hematology
• Molecular Biology
• Cancer Research

Background:

• Acute myeloid leukemia (AML) is a fatal hematologic malignancy with increasing incidence.
• RUNX1 and CEBPA are critical transcription factors in hematopoiesis, frequently mutated in AML.
• TET2 demethylase activity is guided to genomic sites by transcription factors like RUNX1 and CEBPA.

Purpose of the Study:

• To investigate the impact of RUNX1 and CEBPA mutations on DNA methylation in AML.
• To explore the role of TET2 in mediating methylation changes associated with these mutations.
• To assess the therapeutic potential of demethylation strategies in AML.

Main Methods:

• Analysis of DNA methylation patterns in AML patient samples with RUNX1/CEBPA mutations.
• Assessing the interaction between RUNX1, CEBPA, and TET2 in cell lines.
• Evaluating the effect of demethylation therapy on gene expression and chemosensitivity in AML models.

Main Results:

• RUNX1 and CEBPA mutations in AML patients correlate with altered DNA methylation at transcription factor binding sites (TFBS).
• These methylation changes likely silence RUNX1 and CEBPA target genes in a TET2-dependent manner.
• Hypermethylation of TFBS in RUNX1-mutated AML was linked to chemotherapy resistance.
• Demethylation therapy restored BIK gene expression and enhanced AML cell sensitivity to chemotherapy.

Conclusions:

• RUNX1 and CEBPA mutations contribute to AML pathogenesis through aberrant DNA methylation.
• TET2 plays a crucial role in mediating these methylation alterations.
• Demethylation therapy represents a promising strategy to overcome chemotherapy resistance in AML with RUNX1 mutations.